Browse
We’re here to help

Find guidance on Author Services

Login | Register

Login
Register

Cart Add to Cart

Search
Browse
We’re here to help

Find guidance on Author Services

Home
All Journals
Expert Opinion on Investigational Drugs
List of Issues
Volume 32, Issue 10

Expert Opinion on Investigational Drugs

Search in:

Advanced search Citation search

Citation search

Ready to submit?
Start a new submission or continue a submission in progress
Go to submission site
Instructions for authors
Editorial policies
Editing services site

Journal metrics
Aims & scope
Journal information
Editorial board
News & calls for papers
Advertising information

Latest articles
Current issue
All volumes & issues
Special issues
Open access articles
Most read articles
Most cited articles

New content alerts
RSS

Subscription options & pricing

Buy a subscription

Your download is now in progress and you may close this window

Did you know that with a free Taylor & Francis Online account you can gain access to the following benefits?

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Have an account?
Login now Don't have an account?
Register for free

Login or register to access this feature

Have an account?
Login now Don't have an account?
Register for free

Register a free Taylor & Francis Online account today to boost your research and gain these benefits:

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Register now or learn more

Expert Opinion on Investigational Drugs, Volume 32, Issue 10 (2023)

Browse this journal

Latest articles
Current issue
List of issues
Special issues
Open access articles
Most read articles
Most cited articles

Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Expert Opinion on Investigational Drugs, Volume 32, Issue 10 (2023)

See all volumes and issues

Vol 33, 2024 Volume 32, 2023 Vol 31, 2022 Vol 30, 2021 Vol 29, 2020 Vol 28, 2019 Vol 27, 2018 Vol 26, 2017 Vol 25, 2016 Vol 24, 2015 Vol 23, 2014 Vol 22, 2013 Vol 21, 2012 Vol 20, 2011 Vol 19, 2010 Vol 18, 2009 Vol 17, 2008 Vol 16, 2007 Vol 15, 2006 Vol 14, 2005 Vol 13, 2004 Vol 12, 2003 Vol 11, 2002 Vol 10, 2001 Vol 9, 2000 Vol 8, 1999 Vol 7, 1998 Vol 6, 1997 Vol 5, 1996 Vol 4, 1995 Vol 3, 1994

Select to download all citations or PDFs

Download citations Download PDFs Download issue

Browse by section (All)

Display order (Default)
Published online date
Page number
Section A-Z
Most read
Most cited

Editorial

Insights into the anti-inflammatory and anti-arthritic potential of 3-Acetyl-11-keto-β-Boswellic Acid as a therapeutic approach in Rheumatoid Arthritis

Sakshi Priya & Gautam Singhvi

Pages: 867-871

Published online: 06 Nov 2023

First Page PreviewforInsights into the anti-inflammatory and anti-arthritic potential of 3-Acetyl-11-keto-β-Boswellic Acid as a therapeutic approach in Rheumatoid Arthritis | Full Text | References | PDF (1.3 MB) | EPUB

779 Views
0 CrossRef citations
0Altmetric

Free Access

Drug Evaluation

Review Article

MK-0616: an oral PCSK9 inhibitor for hypercholesterolemia treatment

John R. Burnett & Amanda J. Hooper

Pages: 873-878

Published online: 06 Nov 2023

AbstractforMK-0616: an oral PCSK9 inhibitor for hypercholesterolemia treatment | Full Text | References | PDF (278.1 KB) | EPUB

868 Views
0 CrossRef citations
0Altmetric

Review Article

Bomedemstat as an investigative treatment for myeloproliferative neoplasms

Hugh Young Rienhoff Jr. & Harinder Gill

Pages: 879-886

Published online: 06 Nov 2023

AbstractforBomedemstat as an investigative treatment for myeloproliferative neoplasms | Full Text | References | PDF (361 KB) | EPUB

324 Views
0 CrossRef citations
0Altmetric

Review Article

Assessing potential of psilocybin for depressive disorders

Zofia Kozak, Matthew W. Johnson & Scott T. Aaronson

Pages: 887-900

Published online: 06 Nov 2023

312 Views
0 CrossRef citations
0Altmetric

Special Report

Report

Novel JAK inhibitors under investigation for systemic lupus erythematosus: - where are we now?

Shingo Nakayamada & Yoshiya Tanaka

Pages: 901-908

Published online: 06 Nov 2023

AbstractforNovel JAK inhibitors under investigation for systemic lupus erythematosus: - where are we now? | Full Text | References | PDF (772.1 KB) | EPUB

2209 Views
0 CrossRef citations
0Altmetric

Open Access

Report

Current and emerging biological therapies for Chronic rhinosinusitis with nasal polyps with type 2 inflammation

Zeyi Jin, Bing Yan, Luo Zhang & Chengshuo Wang

Pages: 909-919

Published online: 06 Nov 2023

AbstractforCurrent and emerging biological therapies for Chronic rhinosinusitis with nasal polyps with type 2 inflammation | Full Text | References | PDF (1.4 MB) | EPUB

234 Views
0 CrossRef citations
0Altmetric

Review

Review Article

Investigational treatment strategies in glioblastoma: progress made and barriers to success

Thomas A Nelson & Jorg Dietrich

Pages: 921-930

Published online: 06 Nov 2023

AbstractforInvestigational treatment strategies in glioblastoma: progress made and barriers to success | Full Text | References | PDF (292.7 KB) | EPUB

219 Views
0 CrossRef citations
0Altmetric

Review Article

Novel Janus-kinase (JAK) Inhibitors in Myelofibrosis

Yildiz Ipek, Berkay Kilic, Ulgar Boran Gunay & Ahmet Emre Eskazan

Pages: 931-940

Published online: 06 Nov 2023

AbstractforNovel Janus-kinase (JAK) Inhibitors in Myelofibrosis | Full Text | References | PDF (309.7 KB) | EPUB

260 Views
0 CrossRef citations
0Altmetric

Review Article

NF1 alterations in cancers: therapeutic implications in precision medicine

Jean-Stéphane Giraud, Ivan Bièche, Éric Pasmant & Camille Tlemsani

Pages: 941-957

Published online: 06 Nov 2023

428 Views
0 CrossRef citations
0Altmetric

Original Research

Article

A phase I, randomized, double-blind, single-dose pharmacokinetic study to evaluate the biosimilarity of SB16 (proposed denosumab biosimilar) with reference denosumab in healthy male subjects

Hyun A. Lee, Sujung Kim, Hyoryeong Seo & Soyeon Kim

Pages: 959-966

Published online: 06 Nov 2023

AbstractforA phase I, randomized, double-blind, single-dose pharmacokinetic study to evaluate the biosimilarity of SB16 (proposed denosumab biosimilar) with reference denosumab in healthy male subjects | Full Text | References | PDF (630.5 KB) | EPUB

1079 Views
0 CrossRef citations
0Altmetric

Open Access

Explore articles

Latest
Open access
Most read
Most cited
Trending

Explore the most recently published articles

Rheumatoid arthritis extra-articular lung disease: new insights on pathogenesis and experimental drugs

Marco Sebastiani et al.

Review Article | Published online: 5 Jul 2024

Trastuzumab-Deruxtecan in solid tumors with HER2 alterations: from early phase development to the first agnostic approval of an antibody-drug conjugate.

Crimini Edoardo et al.

Review Article | Published online: 5 Jul 2024

Open Access

Monoclonal antibodies targeting interleukins for systemic lupus erythematosus: updates in early clinical drug development

Claudio Cruciani et al.

Review Article | Published online: 3 Jul 2024

VERVE-101, a CRISPR base-editing therapy designed to permanently inactivate hepatic PCSK9 and reduce LDL-cholesterol

Amanda J. Hooper et al.

Editorial | Published online: 21 Jun 2024

Free Access

View all latest articles

Download citations

Choose format

RIS (ProCit, Reference Manager)
BibTeX
RefWorks Direct Export

Download citations

Expert Opinion on Investigational Drugs (Vol.32, Iss.10, 2023)

Access Rights

Only articles that you have access rights to view will be downloaded. The green tick (full access) and orange padlock (open access) icons indicate that you have full access.

Do you want to proceed?